U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[X]  QUARTERLY  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
     EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2003

[ ]  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR 15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934



                         For the transition period from

                          Commission File No. 000-15243

                         VITAL HEALTH TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)

           Minnesota                                         41-1618186
(State or other jurisdiction of                           (I.R.S. Employer
 incorporation or organization)                           Identification No.)


             9454 Wilshire Blvd., Suite 600, Beverly Hills, CA 90212
                    (Address of Principal Executive Offices)

                                 (310) 278-3108
                           (Issuer's telephone number)

                 855 Village Center Drive, North Oaks, MN 55127
                    Former name, address and fiscal year, if
                           changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the issuer was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

Indicate  by check mark  whether  the  registrant  is an  accelerated  filer (as
defined in Rule 12b-2 of the Act). Yes [ ] No [X]


APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the issuer's classes of common
equity, as of May 13, 2003: 3,741, 250 shares of common stock.

Transitional Small Business Format: Yes  [ ]    No  [X]

<PAGE>


                                   FORM 10-QSB



                         VITAL HEALTH TECHNOLOGIES, INC.




                                      INDEX

                                                                          Page

PART I.      FINANCIAL INFORMATION                                        3

Item 1       Financial Statements                                         3

Item 2       Management's Discussion and Analysis of Financial Condition
             and Plan of Operation                                        7

Item 3       Controls and Procedures

PART II.     OTHER INFORMATION                                            8

Item 6       Exhibits and Reports on Form 8-K
                                                                          8
             SIGNATURES
                                                                          9
             CERTIFICATION STATEMENTS



Item 1.     Financial Information


<TABLE>
<CAPTION>

                         VITAL HEALTH TECHNOLOGIES, INC.
                          (A Development Stage Company)

                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (Unaudited)

                                                        March 31,           December 31,
                                                          2003                  2002
                                                        ---------           -----------
              ASSETS
              ------

Current assets:
<S>                                                    <C>                 <C>
    Cash                                               $    111,254        $     11,019
    Prepaid expenses                                             --                 235
    Accounts receivable                                      87,077
                                                       ------------        ------------

         Total current assets                               198,331              11,254
                                                       ------------        ------------

    Other assets                                             16,563                  --
                                                       ------------        ------------

         Total assets                                  $    214,894        $     11,254
                                                       ============        ============

  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
  ----------------------------------------------

Current liabilities:
    Accounts payable and accrued expenses              $     11,397        $     16,105
    Notes payable                                                --              97,500
                                                       ------------        ------------

         Total current liabilities                           11,397             113,605
                                                       ------------        ------------
Long term liabilities:                                      298,246


Stockholders' equity (deficit):
    Undesignated stock: 5,000,000 shares
      authorized; none issued and outstanding                    --                  --
    Common stock: $.01 par value; 50,000,000
      shares authorized; shares issued and
      outstanding 3,741,250 in 2003 and
      3,741,250 in 2002                                      37,413              37,413
    Additional paid-in capital                           12,080,584          12,125,310
    Subscription receivable                                 (15,336)           (110,000)
    Accumulated deficit                                 (11,793,637)        (11,793,637)
    Deficit accumulated during the
      development stage                                    (403,773)           (361,437)
                                                       ------------        ------------

        Total stockholders' equity (deficit)                (94,749)           (102,351)
                                                       ------------        ------------

         Total liabilities and
          Stockholders' equity (deficit)               $    214,894        $     11,254
                                                       ============        ============
</TABLE>

              The accompanying notes are an integral part of these
                              financial statements.


                                       3

<PAGE>


<TABLE>
<CAPTION>

                         VITAL HEALTH TECHNOLOGIES, INC.
                          (A Development Stage Company)

                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)

                                          Three Months Ended
                                      March 31,         March 31,
                              -------------------------------------    Reentrance Into
                                       2003                 2002      To March 31, 2003
                                     ---------            ---------  ---------------------
September 30, 2002
-------------------
<S>                                 <C>              <C>              <C>
Revenues                            $        --               --      $    96,361

Cost of sales    -                           --               --              (38)

General and administrative
  expenses                              (42,336)         (41,817)        (825,263)

Interest expense                             --           (2,727)        (102,143)

Other income (expense)                       --               --           (7,404)

Debt forgiveness                             --               --          435,243

Income tax expense                           --               --             (529)
                                     -----------      -----------      -----------

Net income (loss)                       (42,336)         (44,544)        (403,773)

Other comprehensive
  income (loss)                              --               --               --
                                     -----------      -----------      -----------

Comprehensive income (loss)         $   (42,336)     $   (44,544)     $  (403,773)
                                     ===========      ===========      ===========

Basic earnings (loss) per share     $      (.01)     $      (.02)     $     (0.11)
                                     ===========      ===========      ===========

Weighted average number of
 shares outstanding                   3,741,250        2,594,460        3,741,250
                                     ===========      ===========      ===========
</TABLE>


              The accompanying notes are an integral part of these
                              financial statements.

                                        4

<PAGE>

<TABLE>
<CAPTION>

                         VITAL HEALTH TECHNOLOGIES, INC.
                          (A Development Stage Company)

                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           Increase (Decrease) In Cash
                                   (Unaudited)


                                       Three Months Ended   Development
                                          March 31,           Stage         Reentrance to
                                             2003             2002          March 31, 2003
                                          ---------         ---------     ------------------
Cash flows from operating activities:
<S>                                       <C>             <C>                <C>
   Net income (loss)                        $ (42,336)     $ (44,544)     $(403,773)
   Adjustments to reconcile
        net income (loss) to
        cash flows from operating
        activities:
         Debt forgiveness                          --             --       (435,243)
         Indebtedness incurred
          for services and storage                 --             --        400,000
         Implied compensation under
           SABS-T                                  --         10,000        130,000
         Stock issued for services                 --         23,100         23,100
         Warrants issued for
          consulting services                      --             --          2,012
         Depreciation                              --            363          2,672
         Valuation allowance                       --           (363)         6,878
         Inventory                                 --             38             38
      Accounts receivable                     (87,077)            --             --
       Organization expenses                  (16,563)            --             --
       Prepaid expenses                           235             --             --
      Accounts payable and
       other current liabilities               (4,708)         2,512         (6,610)
                                            ---------      ---------      ---------
Cash flows from operating
  activities                                 (150,449)        (8,932)      (277,677)
                                            ---------      ---------      ---------

Cash flows from investing
  activities:                                      --             --             --

   Stock proceeds                             (44,726)            --         84,888
   Decrease in subscriptions receivable        94,664
   Issuance of convertible
   notes payable                                   --         10,000        167,038
   Principal payments                              --             --        (15,000)
   Increase in long term debt                 200,746             --             --
                                            ---------      ---------      ---------

Cash flows from financing
  activities                                  250,684         10,000        236,926
                                            ---------      ---------      ---------

Increase (decrease) in cash                   100,235          1,068        100,377
Cash:
  Beginning of year                            11,019          1,379         10,877
                                            ---------      ---------      ---------
  End of period                             $ 111,254      $   2,447      $ 111,254
                                            =========      =========      =========

Supplemental cash flow information:
Interest paid                               $      --      $      --      $      --
                                            =========      =========      =========
Income taxes paid                           $      --      $      --      $   1,081
                                            =========      =========      =========

</TABLE>

              The accompanying notes are an integral part of these
                              financial statements.

                                        5

<PAGE>

NOTES TO FINANCIAL STATEMENTS

A.   BASIS OF PRESENTATION

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with generally accepted  accounting  principles for interim financial
information  and  with  the  instructions  to  Form  10-QSB  and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been included.  Consolidated  financial statements have been prepared due to the
combination of Vital Health  Technologies,  Inc. and Caribbean  American  Health
Resorts,  Inc. Operating results for the three-month period ended March 31, 2003
are not necessarily  indicative of the results that may be expected for the year
ended  December  31,  2003.  For  further  information,  refer to the  financial
statements and footnotes  thereto  included in the Company's Form 10-KSB for the
year ended December 31, 2002.

Nature of Business

     The Company was  incorporated on April 1, 1960, under the laws of the State
of  Minnesota.  On  September  26, 2000,  the Company  changed its name to Vital
Health Technologies, Inc. Formerly the Company was known as Vital Heart Systems,
Inc.

     The  Company  has  focused  its  efforts on the design and  marketing  of a
non-invasive,  stress-free coronary artery disease (CAD) detection device called
a Variance Cardiograph.

     From  1993 to 1998  the  Company  struggled  with a  variety  of  financial
difficulties,  which  limited  operations.  Since  1998  through  March 2003 the
Company has worked  with a Minnesota  finance  and  business  development  firm,
Aurora Capital Management, LLC and its affiliates in an effort to revitalize the
Company.

     In March 2003,  the Company  executed  and  entered  into a Share  Exchange
Agreement (the "Exchange  Agreement"),  with Caribbean  American Health Resorts,
Inc. Pursuant to the Exchange  Agreement,  on the closing date, the Company will
acquire all of the issued and outstanding equity interests of Caribbean American
Health  Resorts,Inc.  As consideration for the shares Caribbean  American Health
Resorts, Inc, the Company will issue 8,109,709 shares of its common stock to the
shareholders  of Caribbean  American  Health  Resorts,  Inc.  Subsequent  to the
closing  of this  transaction,  and a  concurrent  transaction  whereby  certain
shareholders of the Company are selling  1,640,709 common shares,  the remaining
stockholders of the Company shall retain 250,000 shares, or 2 1/2% of the issued
and outstanding common stock of the Company on an anti-dilutive  basis (only for
90 days  after  the  closing).  As part of this  transaction,  certain  existing
shareholders of the Company shall form a separate entity for the sole purpose of
purchasing  the heart  screening  technology  of the  Company  in  exchange  for
returning to the Company 1,850,000 shares of Company common stock presently held
by such shareholders.

     The  Company's  common  stock  currently  trades on the NASD's OTC Bulletin
Board exchange under the ticker symbol CAHR.

Development Stage Company

     The Company has devoted the majority of its efforts to:  maintenance of the
corporate  status;  settlement of  liabilities;  technology  development and the
search for a viable method of operations and/or merger candidate.

     Since  1998  the  Company  has  been  fully  dependent  on  Aurora  and its
affiliates  for the  maintenance  of its  corporate  status and to  provide  all
managerial assistance and working capital support for the Company.

     In 2001 the Company successfully developed a new prototype for its Variance
Cardiograph  heart disease  testing  device that shortens the test time from the
original  45-minute  version to 10-minutes,  while at the same time reducing the
cost of manufacturing significantly. The Company completed field-testing and has
systems  installed  at  two  locations  in the  St.  Paul/Minneapolis  area  for
evaluation purposes.

     The  Company  holds and  maintains  a patent on its  Variance  Cardiography
technology that was issued in 1993.

     On January 30,  2002 the Company  entered  into an  agreement  with a Texas
based finance and consulting firm, Focus Tech Investments,  Inc. (FTI) where FTI
will provide periodic  financing and will seek out potential  merger/acquisition
candidates  for the Company.  The original  agreement  with FTI was to expire on
August  30,  2002.  The  Company  and FTI have  agreed  to an  extension  for an
additional 180 days as the Company is having discussions with candidates FTI has
introduced.

     On April 23, 2002 the Company entered into a stock purchase  agreement with
Templar  Comptier,  Ltd whereas the Company sold 1,146,250  shares of its common
stock for $350,000. Templar Comptier has paid $50,000 in cash for 146,250 shares
that have been  delivered and the Company holds a 180-day note for $300,000 with
the remaining 1,000,000 shares being held as collateral against the note.

     The Company utilized the proceeds for ongoing  administrative  costs,  debt
payment and to finance  merger/acquisition  expenses.  The Company filed an SB-2
registration  with the SEC for the shares issued to Templar  Comptier,  Ltd. and
386,224  shares that were  previously  issued to  shareholders  of Vital  Health
Technologies.

     In March 2003,  the Company  executed  and  entered  into a Share  Exchange
Agreement (the "Exchange  Agreement"),  with Caribbean  American Health Resorts,
Inc. Pursuant to the Exchange  Agreement,  on the closing date, the Company will
acquire all of the issued and outstanding equity interests of Caribbean American
Health  Resorts,Inc.  As consideration for the shares Caribbean  American Health
Resorts, Inc, the Company will issue 8,109,709 shares of its common stock to the
shareholders  of Caribbean  American  Health  Resorts,  Inc.  Subsequent  to the
closing  of this  transaction,  and a  concurrent  transaction  whereby  certain
shareholders of the Company are selling  1,640,709 common shares,  the remaining
stockholders of the Company shall retain 250,000 shares, or 2 1/2% of the issued
and outstanding common stock of the Company on an anti-dilutive  basis (only for
90 days  after  the  closing).  As part of this  transaction,  certain  existing
shareholders of the Company shall form a separate entity for the sole purpose of
purchasing  the heart  screening  technology  of the  Company  in  exchange  for
returning to the Company 1,850,000 shares of Company common stock presently held
by such shareholders.



Item 2. Management's Discussion and Analysis of Financial Condition and Plan of
Operation

Three Months Ended March 31, 2003 and  March 31, 2002

     We generated no revenue for the three months ended March 31, 2003, as
compared to no revenue for the three months ended March31,2002. Cost of sales
for the three months ended March 31, 2003 and 2002were $0 and $0, respectively.

     General and administrative expenses for the three months ended March
31,2003 were $42,336 as compared to $41,817 in the same period of 2002.

     We had interest expense in the amount of $0 for the three months ended
March 31,2003, as compared to $2,727 interest expense for the three months ended
March 31, 2002.

     As a result of the foregoing, we realized a net loss of $42,336 for the
three months ended March 31,2003, as compared to a net loss of $44,544 for the
same period in 2002.

Liquidity and Capital Resources

     At March 31, 2003, we had a working capital of $111,254, as compared to a
working capital $11,019 at December 31, 2002. The change is primarily due to the
merger with Caribbean American Health Resorts,Inc.

Plan for the next 12 months.

     Our plan for the next 12 months is to handle the administrative and
reporting requirements of a public company. .The Company also plans to acquire
two hotel properties on the island of Barbados. The properties will be developed
into condominiums. It is expected that these condominiums will be sold to
doctors and surgeons who will perform surgical procedures and other alternative
medical treatmnets to their clients on the island. The Company is expected to
enter into an agreement in principle to lease a surgical facilty on the island
to perform the various cosmetic and reconstructive surgical procedures.

Item 3.  Controls and Procedures

     Within the 90 days prior to the date of this Form 10-QSB, the Company
carried out an evaluation, under the supervision and with the participation of
the Company's management, including the Company's Chief Executive Officer and
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures pursuant to Exchange Act Rule
13a-14. Based upon that evaluation, the Company's Chief Executive Officer/Chief
Financial Officer concluded that the Company's disclosure controls and
procedures are effective in timely alerting them to material information
relating to the Company required to be included in the Company's periodic SEC
filings. There have been no significant changes in the Company's internal
controls or in other factors, which could significantly affect internal controls
subsequent to the date the Company carried out its evaluation.


<PAGE>

Forward-Looking Statement Notice

     When used in this report, the words "may," "will," "expect," "anticipate,"
"continue," "estimate," "project," "intend," and similar expressions are
intended to identify forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934 regarding events, conditions, and financial trends that may affect our
future plans of operations, business strategy, operating results, and financial
position. Persons reviewing this report are cautioned that any forward-looking
statements are not guarantees of future performance and are subject to risks and
uncertainties and that actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Such
factors are discussed above and also include general economic factors and
conditions that may directly or indirectly impact our financial condition or
results of operations.

PART II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K.

(a) Exhibits required by Item 601 of Regulation S-B

99.1     Certification of Chief Executive Officer
99.2     Certification of Chief Financial Officer

(b) Reports on Form 8-K.

Report on Form 8-K filed March 25, 2003 reporting change of control of the
Company pursuant to a Share Exchange Agreement , dated as of March 10, 2003, by
and between the Company and Caribbean American Health Resorts, Inc. (CAHR).
Pursuant to the Share Exchange Agreement, on the closing date, the Company will
acquire from the shareholders of CAHR all of the issued and outstanding equity
interests of CAHR.


                                   SIGNATURES

        In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                         Vital Health Technologies, Inc.

Date: May 13, 2003       By:  /s/  Halton Martin
                         =================================
                         Halton Martin, Director,
                         Principal Financial Officer and
                         Principal Executive Officer


                                        8

<PAGE>

                                CERTIFICATION OF
                           PRINCIPAL EXECUTIVE OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

I, Halton Martin, Principal Executive Officer, certify that:

1.     I have reviewed this quarterly report on Form 10-QSB of Vital Health
       Technologies, Inc.

2.     Based on my knowledge, this quarterly report does not contain any untrue
       statement of a material fact or omit to state a material fact necessary
       to make the statements made, in light of the circumstances under which
       such statements were made, not misleading with respect to the period
       covered by this quarterly report;

3.     Based on my knowledge, the financial statements, and other financial
       information included in this quarterly report, fairly present in all
       material respects the financial condition, results of operations and cash
       flows of the registrant as of, and for, the periods presented in this
       quarterly report;

4.     The registrant's other certifying officers and I are responsible for
       establishing and maintaining disclosure controls and procedures (as
       defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
       have:

       a)     designed such disclosure controls and procedures to ensure that
              material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within
              those entities, particularly during the period in which this
              quarterly report is being prepared;

       b)     evaluated the effectiveness of the registrant's disclosure
              controls and procedures as of a date with 90 days prior to the
              filing date of this quarterly report (the "Evaluation Date"); and

       c)     presented in this quarterly report our conclusions about
              effectiveness of the disclosure controls and procedures based on
              our evaluation as of the Evaluation Date;

5.     The registrant's other certifying officers and I have disclosed, based on
       our most recent evaluation, to the registrant's auditors and the audit
       committee of registrant's board of directors (or persons performing the
       equivalent functions):

       a)     all significant deficiencies in the design or operation of
              internal controls which could adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant's auditors and material
              weakness in internal controls; and

       b)     any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls; and

<PAGE>



       The registrant's other certifying officers and I have indicated in this
       quarterly report whether there were significant changes in internal
       controls or in other factors that could significantly affect internal
       controls subsequent to the date of
6. our most recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.



Dated:     May 13,  2003

/s/   Halton Martin
==========================================
Halton Martin, Principal Executive Officer


<PAGE>

                                CERTIFICATION OF
                           PRINCIPAL FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

I, Halton Martin, Principal Financial Officer, certify that:

1.     I have reviewed this quarterly report on Form 10-QSB of Vital Health
       Technologies, Inc.

2.     Based on my knowledge, this quarterly report does not contain any untrue
       statement of a material fact or omit to state a material fact necessary
       to make the statements made, in light of the circumstances under which
       such statements were made, not misleading with respect to the period
       covered by this quarterly report;

3.     Based on my knowledge, the financial statements, and other financial
       information included in this quarterly report, fairly present in all
       material respects the financial condition, results of operations and cash
       flows of the registrant as of, and for, the periods presented in this
       quarterly report;

4.     The registrant's other certifying officers and I are responsible for
       establishing and maintaining disclosure controls and procedures (as
       defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
       have:

       a)     designed such disclosure controls and procedures to ensure that
              material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within
              those entities, particularly during the period in which this
              quarterly report is being prepared;

       b)     evaluated the effectiveness of the registrant's disclosure
              controls and procedures as of a date with 90 days prior to the
              filing date of this quarterly report (the "Evaluation Date"); and

       c)     presented in this quarterly report our conclusions about
              effectiveness of the disclosure controls and procedures based on
              our evaluation as of the Evaluation Date;

5.     The registrant's other certifying officers and I have disclosed, based on
       our most recent evaluation, to the registrant's auditors and the audit
       committee of registrant's board of directors (or persons performing the
       equivalent functions):

       a)     all significant deficiencies in the design or operation of
              internal controls which could adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant's auditors and material
              weakness in internal controls; and

       b)     any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls; and

<PAGE>



       The registrant's other certifying officers and I have indicated in this
       quarterly report whether there were significant changes in internal
       controls or in other factors that could significantly affect internal
       controls subsequent to the date of
6. our most recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.



Dated:     May 13,  2003

/s/    Halton Martin
==========================================
Halton Martin, Principal Financial Officer